http://www.cnr.it/ontology/cnr/individuo/prodotto/ID37769
Rimonabant: the first therapeutically relevant cannabinoid antagonist (Articolo in rivista)
- Type
- Label
- Rimonabant: the first therapeutically relevant cannabinoid antagonist (Articolo in rivista) (literal)
- Anno
- 2005-01-01T00:00:00+01:00 (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
- 10.1016/j.lfs.2005.04.017 (literal)
- Alternative label
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
- Carai M.A.M., Colombo G., Gessa G.L. (literal)
- Pagina inizio
- Pagina fine
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
- Rivista
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
- Note
- ISI Web of Science (WOS) (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
- \"Bernard B. Brodie\" Department of Neuroscience, University of Cagliari, Cagliari (CA), Italy; C.N.R. Institute of Neuroscience, Section of Cagliari, Cagliari (CA), Italy. (literal)
- Titolo
- Rimonabant: the first therapeutically relevant cannabinoid antagonist (literal)
- Abstract
- The present paper synthetically reviews the multiple experimental lines of evidence indicating the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant (also known as SR 141716), to suppress the reinforcing/rewarding properties of different drugs of abuse, including cocaine, heroin, nicotine and alcohol, in laboratory rodents. This paper also reviews the data demonstrating that rimonabant reduces food intake and body weight in laboratory animals and humans. Taken together, the data reviewed here suggest that rimonabant may constitute a new and potentially effective medication for the treatment of drug addiction and obesity-related disorders. (literal)
- Prodotto di
- Autore CNR
- Insieme di parole chiave
Incoming links:
- Autore CNR di
- Prodotto
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
- Insieme di parole chiave di
